PPP1R16B

Across TCGA pan-cancer cohorts, PPP1R16B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PPP1R16B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PPP1R16B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PPP1R16B is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where PPP1R16B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PPP1R16B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	−0.632	<.001	8	view →
LSCC	Male	III,IV	−0.767	<.001	7	view →
LUAD	All	All	−0.361	<.001	5	view →
HNSC	All	III,IV	+0.880	.016	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

PPP1R16B–CCRCC

Open the CCRCC breakdown →